News >

EU Panel Backs Maintenance Rucaparib for Ovarian Cancer

Gina Columbus @ginacolumbusonc
Published: Thursday, Dec 13, 2018

Jonathan Ledermann MD, FRCP
Jonathan Ledermann MD, FRCP
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended to expand the approval of single-agent rucaparib (Rubraca) as a maintenance therapy in adult patients with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Community Practice Connections™: 2nd Annual International Congress on Oncology Pathology™Aug 31, 20191.5
Publication Bottom Border
Border Publication
x